Smith & Nephew plc (LON:SN - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,057.99 ($13.70) and traded as high as GBX 1,165 ($15.09). Smith & Nephew shares last traded at GBX 1,141 ($14.78), with a volume of 2,833,536 shares.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. reiterated an "overweight" rating and set a GBX 1,180 ($15.28) price target on shares of Smith & Nephew in a report on Tuesday, January 14th.
Get Our Latest Stock Analysis on SN
Smith & Nephew Price Performance
The stock has a market capitalization of £12.02 billion, a price-to-earnings ratio of 39.46, a PEG ratio of 0.46 and a beta of 0.62. The business's fifty day moving average price is GBX 1,046.31 and its 200-day moving average price is GBX 1,058.57. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84.
Insider Activity
In other news, insider John Rogers purchased 71,920 shares of the business's stock in a transaction that occurred on Thursday, December 19th. The shares were acquired at an average cost of GBX 972 ($12.59) per share, for a total transaction of £699,062.40 ($905,521.24). Corporate insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
